SPONSOR
argenx
Total Trials
5
Recruiting
5
Phases
Phase 2, Phase 3, Phase 1
Conditions studied: AChR-Ab Seropositive Generalized Myasthenia GravisMyasthenia Gravis (MG)MG - Myasthenia GravisgMGGraves' DiseaseGraves DiseasePrimary Immune Thrombocytopenia (ITP)Healthy VolunteerHealthy Adult Participants
argenx is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG.
The trial portfolio spans Phase 2, Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — argenx
How many clinical trials has argenx sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by argenx, of which 5 are actively recruiting participants. These trials cover conditions including AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does argenx research focus on?
argenx clinical trials span AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG, Graves' Disease, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a argenx clinical trial?
To participate in a argenx trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all argenx trials with current recruitment status updated daily.
Clinical Trials by argenx
NCT07673627 Phase 2
Recruiting
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
AChR-Ab Seropositive Generalized Myasthenia Gravis
NCT07570316 Phase 3
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Graves' Disease
NCT07596849 Phase 3
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
Graves Disease
NCT06544499 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia (ITP)
NCT07782775 Phase 1
Recruiting
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants
Healthy Volunteer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology